Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials
Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials
复制标题
DOI：
10.1111/j.1365-2141.2008.07492.x
复制
发表时间：
2009-02-01
影响因子：
6.5
通讯作者：
Atkinson, Kerry
中科院分区：
文献类型：
--
作者：
Brooke, Gary;Rossetti, Tony;Atkinson, Kerry
间充质干细胞(MSC)越来越多地用于治疗一系列再生性和炎症性疾病的临床试验。骨髓是传统的来源，但相对大容量是无法获得的。目前，间充质干细胞来源于骨髓以外的组织，包括胎盘和脂肪组织。我们使用分娩后获得的胎盘作为MSC的来源，但一直无法检测到与骨髓来源的MSC在细胞表面表型、趋化因子受体显示、中胚层分化能力或免疫抑制能力方面的任何显著差异。这份报告描述了我们分离和扩增人胎盘来源的MSC的制造过程，并将它们安全地输注到第一个人胎盘来源的MSC临床试验计划的患者中。
Mesenchymal stem cells (MSC) are being used increasingly in clinical trials for a range of regenerative and inflammatory diseases. Bone marrow is the traditional source but is relatively inaccessible in large volume. MSC have now been derived from tissues other than bone marrow including placenta and adipose tissue. We have used placenta obtained after delivery as a source of MSC and have been unable to detect any marked differences from marrow-derived MSC in terms of cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability. This report described our manufacturing process for isolating and expanding placenta-derived human MSC and their safe infusion into the first patient in a clinical trial program of human placenta-derived MSC.